Holders — by stockHoldings — by fund
Estuary Capital Management LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0001965005
$857.4M
disclosed book value
25
positions
6.5%
largest position share
Positions, as of 2026-09-30
top 25 of 25 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | OWLBLUE OWL CAPITAL INC | 6.2M | $56.0M | 6.5% |
| 2 | AMZNAMAZON COM INC | 221,523 | $55.2M | 6.4% |
| 3 | AMATAPPLIED MATLS INC | 101,210 | $51.8M | 6% |
| 4 | AAPADVANCE AUTO PARTS INC | 1.3M | $51.6M | 6% |
| 5 | LRCXLAM RESEARCH CORP | 156,874 | $51.5M | 6% |
| 6 | COHRCOHERENT CORP | 176,720 | $50.9M | 5.9% |
| 7 | TERTERADYNE INC | 122,226 | $49.0M | 5.7% |
| 8 | LITELUMENTUM HLDGS INC | 48,565 | $47.2M | 5.5% |
| 9 | ALABASTERA LABS INC | 126,425 | $45.0M | 5.2% |
| 10 | TDGTRANSDIGM GROUP INC | 35,660 | $38.6M | 4.5% |
| 11 | ICFIICF INTL INC | 462,191 | $38.4M | 4.5% |
| 12 | MXLMAXLINEAR INC | 388,138 | $35.1M | 4.1% |
| 13 | CACICACI INTL INC | 56,892 | $34.7M | 4% |
| 14 | GPNGLOBAL PMTS INC | 390,498 | $31.9M | 3.7% |
| 15 | CHYMCHIME FINL INC | 1.1M | $30.1M | 3.5% |
| 16 | OMDAOMADA HEALTH INC | 1.3M | $27.9M | 3.2% |
| 17 | GLBEGLOBAL E ONLINE LTD | 642,661 | $25.5M | 3% |
| 18 | ARESARES MANAGEMENT CORPORATION | 214,928 | $25.0M | 2.9% |
| 19 | FOXFFOX FACTORY HLDG CORP | 1.3M | $24.3M | 2.8% |
| 20 | MNROMONRO INC | 1.6M | $21.7M | 2.5% |
| 21 | NVDANVIDIA CORPORATION | 74,450 | $17.0M | 2% |
| 22 | TOSTTOAST INC | 564,915 | $16.4M | 1.9% |
| 23 | COOCOOPER COS INC | 275,716 | $15.6M | 1.8% |
| 24 | HNGEHINGE HEALTH INC | 89,673 | $8.7M | 1% |
| 25 | MSFTMICROSOFT CORP | 16,560 | $8.5M | 1% |
Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.